These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 10213231)

  • 1. Loss of HLA haplotype in lung cancer cell lines: implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer.
    Hiraki A; Kaneshige T; Kiura K; Ueoka H; Yamane H; Tanaka M; Harada M
    Clin Cancer Res; 1999 Apr; 5(4):933-6. PubMed ID: 10213231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.
    Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Muramatsu M; Yamaguchi K; Fukuhara S
    J Cancer Res Clin Oncol; 2002 Nov; 128(11):581-8. PubMed ID: 12458337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Tissue array analysis of the aberrant expression of HLA class I molecules in human non small cell lung cancer].
    Suzuki H; Higuchi M; Hasegawa T; Yonechi A; Ohsugi J; Yamada F; Hoshino M; Shio Y; Fujiu K; Gotoh M
    Gan To Kagaku Ryoho; 2006 Nov; 33(12):1713-6. PubMed ID: 17212084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Altered HLA class I expression in non-small cell lung cancer is independent of c-myc activation.
    Redondo M; Ruiz-Cabello F; Concha A; Cabrera T; Pérez-Ayala M; Oliva MR; Garrido F
    Cancer Res; 1991 May; 51(9):2463-8. PubMed ID: 1849792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancer.
    So T; Takenoyama M; Mizukami M; Ichiki Y; Sugaya M; Hanagiri T; Sugio K; Yasumoto K
    Cancer Res; 2005 Jul; 65(13):5945-52. PubMed ID: 15994973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines.
    Marincola FM; Shamamian P; Alexander RB; Gnarra JR; Turetskaya RL; Nedospasov SA; Simonis TB; Taubenberger JK; Yannelli J; Mixon A
    J Immunol; 1994 Aug; 153(3):1225-37. PubMed ID: 8027550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer.
    Gamzatova Z; Villabona L; van der Zanden H; Haasnoot GW; Andersson E; Kiessling R; Seliger B; Kanter L; Dalianis T; Bergfeldt K; Masucci GV
    Tissue Antigens; 2007 Sep; 70(3):205-13. PubMed ID: 17661908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
    Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
    Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of HLA class I and II antigens in bronchogenic carcinomas: its relationship to cellular DNA content and clinical-pathological parameters.
    Redondo M; Concha A; Oldiviela R; Cueto A; Gonzalez A; Garrido F; Ruiz-Cabello F
    Cancer Res; 1991 Sep; 51(18):4948-54. PubMed ID: 1654207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer.
    Yazawa T; Kamma H; Fujiwara M; Matsui M; Horiguchi H; Satoh H; Fujimoto M; Yokoyama K; Ogata T
    J Pathol; 1999 Jan; 187(2):191-9. PubMed ID: 10365094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxic properties of CD4(+) T-cell clones which lyse HLA class II negative autologous non-small-cell lung cancer cells.
    Semino C; Ferlazzo G; Ratto GB; Melioli G
    Cell Immunol; 1999 Sep; 196(2):87-94. PubMed ID: 10527560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis.
    Riemersma SA; Oudejans JJ; Vonk MJ; Dreef EJ; Prins FA; Jansen PM; Vermeer MH; Blok P; Kibbelaar RE; Muris JJ; Schuuring EM; Kluin PM
    J Pathol; 2005 Jul; 206(3):328-36. PubMed ID: 15887291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences.
    Grandis JR; Falkner DM; Melhem MF; Gooding WE; Drenning SD; Morel PA
    Clin Cancer Res; 2000 Jul; 6(7):2794-802. PubMed ID: 10914726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma.
    Ibrahim EC; Guerra N; Lacombe MJ; Angevin E; Chouaib S; Carosella ED; Caignard A; Paul P
    Cancer Res; 2001 Sep; 61(18):6838-45. PubMed ID: 11559559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oct-1 DNA binding activity unresponsive to retinoblastoma protein expression prevents MHC class II induction in a non-small cell lung carcinoma cell line.
    Osborne AR; Zhang H; Blanck G
    Mol Immunol; 2006 Feb; 43(6):710-6. PubMed ID: 16360016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HLA-G expression in malignant melanoma.
    Rebmann V; Wagner S; Grosse-Wilde H
    Semin Cancer Biol; 2007 Dec; 17(6):422-9. PubMed ID: 17689098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of HLA class I alleles on postoperative prognosis of lung cancer patients in Japan.
    Nagata Y; Hanagiri T; Mizukami M; Kuroda K; Shigematsu Y; Baba T; Ichiki Y; Yasuda M; So T; Takenoyama M; Sugio K; Nagashima A; Yasumoto K
    Lung Cancer; 2009 Jul; 65(1):91-7. PubMed ID: 19054590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The antigen processing machinery of class I human leukocyte antigens: linked patterns of gene expression in neoplastic cells.
    Giorda E; Sibilio L; Martayan A; Moretti S; Venturo I; Mottolese M; Ferrara GB; Cappellacci S; Eibenschutz L; Catricalà C; Grammatico P; Giacomini P
    Cancer Res; 2003 Jul; 63(14):4119-27. PubMed ID: 12874016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
    Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
    Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.